Hindustan Bio Sciences Limited (BOM:532041)
India · Delayed Price · Currency is INR 7.20
+0.16 (2.27%)
At close: Jul 31, 2026
Hindustan Bio Sciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 4.15 | 7.37 | 8.13 | 10.53 | 9.22 | 4.31 |
Other Revenue | -0.13 | - | - | - | - | - |
| 4.02 | 7.37 | 8.13 | 10.53 | 9.22 | 4.31 | |
Revenue Growth | -44.38% | -9.37% | -22.75% | 14.15% | 114.19% | -58.27% |
Cost of Revenue | 2.37 | 4.49 | 4.97 | 6.44 | 5.79 | 2.48 |
Gross Profit | 1.65 | 2.88 | 3.16 | 4.09 | 3.44 | 1.82 |
Selling, General & Admin | 2.05 | 1.94 | 1.32 | 1.65 | 2.62 | 2.53 |
Other Operating Expenses | 1.45 | 1.53 | 0.84 | 1.8 | 1.1 | 4.31 |
Operating Expenses | 3.71 | 3.66 | 2.17 | 3.52 | 3.77 | 6.87 |
Operating Income | -2.06 | -0.78 | 1 | 0.57 | -0.34 | -5.05 |
Interest Expense | -0.01 | -0.01 | - | - | - | - |
Currency Exchange Gain (Loss) | - | - | - | - | - | -0.05 |
Other Non Operating Income (Expenses) | - | 0 | -0.02 | -0.04 | -0.04 | -0.05 |
EBT Excluding Unusual Items | -2.06 | -0.79 | 0.98 | 0.53 | -0.38 | -5.14 |
Pretax Income | -2.06 | -0.79 | 0.98 | 0.53 | -0.38 | -5.14 |
Income Tax Expense | -0 | -0 | -0.03 | -0.04 | 0.03 | 0.03 |
Net Income | -2.06 | -0.79 | 1.01 | 0.58 | -0.4 | -5.18 |
Net Income to Common | -2.06 | -0.79 | 1.01 | 0.58 | -0.4 | -5.18 |
Net Income Growth | - | - | 74.83% | - | - | - |
Shares Outstanding (Basic) | 9 | 10 | 10 | 10 | 10 | 10 |
Shares Outstanding (Diluted) | 9 | 10 | 10 | 10 | 10 | 10 |
Shares Change | -19.01% | -3.79% | - | - | - | - |
EPS (Basic) | -0.23 | -0.08 | 0.10 | 0.06 | -0.04 | -0.50 |
EPS (Diluted) | -0.23 | -0.08 | 0.10 | 0.06 | -0.04 | -0.50 |
EPS Growth | - | - | 74.83% | - | - | - |
Free Cash Flow | - | -1.36 | 0.27 | -14.09 | -0.5 | -3.46 |
Free Cash Flow Per Share | - | -0.14 | 0.03 | -1.38 | -0.05 | -0.34 |
Gross Margin | 41.03% | 39.09% | 38.89% | 38.84% | 37.26% | 42.33% |
Operating Margin | -51.11% | -10.61% | 12.25% | 5.42% | -3.67% | -117.17% |
Profit Margin | -51.18% | -10.70% | 12.38% | 5.47% | -4.39% | -120.19% |
Free Cash Flow Margin | - | -18.40% | 3.33% | -133.83% | -5.40% | -80.41% |
EBITDA | -1.81 | -0.58 | 1 | 0.64 | -0.28 | -5.01 |
EBITDA Margin | -44.93% | -7.91% | 12.27% | 6.07% | -3.06% | -116.38% |
D&A For EBITDA | 0.25 | 0.2 | 0 | 0.07 | 0.06 | 0.03 |
EBIT | -2.06 | -0.78 | 1 | 0.57 | -0.34 | -5.05 |
EBIT Margin | -51.11% | -10.61% | 12.25% | 5.42% | -3.67% | -117.17% |
Revenue as Reported | 4.02 | 7.37 | 8.13 | 10.53 | 9.22 | 4.31 |
Advertising Expenses | - | - | 0.05 | 0.07 | 0.07 | 0.06 |